Dr. Wael Dakkak, MD

Dr. Dakkak practices at CHRISTUS Mother Frances Hospital - Clinic Services - Douglas - HOPD in Tyler, Texas.

Dr. Dakkak's NPI, 1417308065, was assigned on June 24, 2016. Dr. Dakkak holds Illinois license 125.069420.

Dr. Dakkak's primary practice is CHRISTUS Mother Frances Hospital - Clinic Services - Douglas - HOPD, at 520 Douglas Blvd, Tyler, TX 75702.

Dr. Dakkak's primary practice is CHRISTUS Mother Frances Hospital - Clinic Services - Douglas - HOPD in Tyler, Texas. Dr. Dakkak is also affiliated with CHRISTUS Santa Rosa Hospital - Westover Hills. The medical group on file is CHRISTUS Trinity Clinic. Dmand AI also links Dr. Dakkak to 1 more group practice or clinic, 1 urgent care center and 1 medical group, each named with a free account. Dr. Dakkak's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Dakkak practices, 4 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Dakkak's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Dakkak is licensed in Illinois.

CMS data shows 147 Medicare services from Dr. Dakkak across 4 procedure codes in 2024, for 105 Medicare patients. Medicare paid $11,842 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 105 Medicare patients who saw Dr. Dakkak in 2024. The largest group is 75 to 84, with 42 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 2.32, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Dakkak's median patient age at 62, with 54% women.

In 2024, Dr. Dakkak wrote 319 Medicare Part D claims for 74 patients. 72% of them were for generic drugs. CMS names the drug for 204 of them, across 7 drugs with 11 or more claims each, at $49,971 in total drug cost. In 2023, CMS named 140 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 95 out of 100 for Dr. Dakkak for performance year 2024, reported through an alternative payment model (APM). Dr. Dakkak accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 63 general payments to Dr. Dakkak from 16 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 93% of the total. Abiomed paid the most, $1,112.